{"id":149958,"date":"2026-08-21T12:39:11","date_gmt":"2026-08-21T12:39:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/149958\/"},"modified":"2026-08-21T12:39:11","modified_gmt":"2026-08-21T12:39:11","slug":"zepbound-maker-eli-lilly-is-in-a-race-with-novo-nordisk-but-its-stock-is-the-clear","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/149958\/","title":{"rendered":"Zepbound Maker Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear"},"content":{"rendered":"<p>Zepbound maker and drug giant Eli Lilly&#8217;s (LLY) stock is in the buy zone of a flat base\u00a0after hitting a new high. The IBD Sector Leaders name is in a race with Novo Nordisk (NVO) in the fast-growing weight-loss medication industry. Lilly makes injectable obesity drug Zepbound and Type 2 diabetes treatment Mounjaro. It launched its weight-loss pill Foundayo in\u2026<\/p>\n<p>Copyright \u00a92026 Investor&#8217;s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8<\/p>\n","protected":false},"excerpt":{"rendered":"Zepbound maker and drug giant Eli Lilly&#8217;s (LLY) stock is in the buy zone of a flat base\u00a0after&hellip;\n","protected":false},"author":2,"featured_media":149959,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[45688,45689,70949,270,272],"class_list":["post-149958","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-all-news-and-stock-ideas","tag-biotech-and-pharma-stock-news","tag-chart-patterns-flat-base","tag-earnings","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117133545691096437","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/149958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=149958"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/149958\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/149959"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=149958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=149958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=149958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}